China Cracks Down on Monopolies in Active Pharmaceutical Ingredient Industry

by Grace Wang Nov 26, 2021

On Nov. 18, China issued the Anti-Monopoly Guidance for Active Pharmaceutical Ingredients (hereafter referred to as API Anti-Monopoly Guidance or Guidance), clarifying regulations against monopoly agreements, abuse of market power, and concentration of undertakings that limits or excludes competition.1

The API Anti-Monopoly Guidance, published by the State Council's Anti-Monopoly Committee, marks China's first detailed guidance for enforcing the Anti-Monopoly Law in the pharmaceutical industry.

This article is meant to introduce the Guidance's application scope, interpret its highlight anti-monopoly regulations, and analyze its influence on China's pharma industry.

API Anti-Monopoly Guidance's Application Scope

The Guidance applies to

  1. APIs: the active ingredients which serve as effective components in finished drug products, including chemical drug products' active ingredients and traditional Chinese medicines' raw materials. and

  2. chemical raw materials and pharmaceutical intermediates used for producing APIs and pharmaceutical excipients in the upstream supply chain .

Highlights of API Anti-Monopoly Guidance

Grace Wang
ChemLinked Regulatory Analyst
Copyright: unless otherwise stated all contents of this website are ©2022 - REACH24H Consulting Group - All Rights Reserved - For permission to use any content on this site, please contact